New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate.
John C Davis, Feng Huang, Walter Maksymowych
https://pubmed.ncbi.nlm.nih.gov/12951863/Completed
Phase 2
Age: 18Years - 80Years
All Genders
ID00000433
Anti-Tumor Necrosis Factor TNFRFc in Ankylosing Spondylitis
Led by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Updated on 2007-01-04
42
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
The Division of Rheumatology at University of California San Francisco is conducting a research study on the treatment of ankylosing spondylitis (AS) with a new therapy currently used for people with other forms of arthritis. The drug, called Enbrel (or etanercept), is a protein that is given twice weekly by injection underneath the skin. It blocks the action of tumor necrosis factor-alpha (TNF-alpha), a substance that may be involved in AS, rheumatoid arthritis, and other inflammatory conditions. We will randomly assign patients to receive either the drug or a placebo (inactive treatment) for 4 months. The results we will monitor include morning stiffness, spinal mobility, activities of daily life, and safety of the drug.
CONDITIONS
Brief Title
Blocking Tumor Necrosis Factor in Ankylosing Spondylitis
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here